MTOR and breast cancer: Proof-of-principal for the value of osteoblast stimulation in the treatment of osteolytic breast cancer metastases was suggested by exploratory studies of bone parameters (reviewed [11] in the BOLERO-2 (Breast cancer trials of Oral Everolimus-2) trial (exemestane + the mTOR inhibitor everolimus) [12].